Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
ALK-Abelló beats Q4 expectations and proposes dividend
ALK-Abelló reports Q4 revenue of DKK 1.73bn (3% above consensus) and EBIT of DKK 387m (5% above consensus). The EBIT margin rose to 22.3%, but net profit fell short of expectations due to higher taxes. The company proposes a dividend of DKK 1.60 per share for the first time since 2017 and expects 2026 revenue growth of 11–15% (DKK 6.9–7.2bn) with an EBIT margin of around 25%. ALK-Abelló also announced the resignation of its head of research & development and has begun the search for a successor. » More on de.investing.com
Alk-Abello A-S discloses quarterly figures for end of December
Alk-Abello A-S reports on the quarter to 31.12.2025 on 20.02.2026. One analyst expects EPS of 1.30 DKK versus 0.770 DKK in the year-ago quarter. Four analysts see revenue at an average of 1.71 billion DKK, up 13.81 percent from 1.50 billion DKK. For the fiscal year analysts on average forecast EPS of 5.63 DKK (prior year 3.68 DKK) on revenue of 6.27 billion DKK (prior year 5.54 billion DKK). » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsIn 2026, ALK-Abelló B Aktie has already paid €0.21 in dividends. The last payout was in March.
Financials
In the last quarter, ALK-Abelló B Aktie had revenue of €230.31M and net profit of €47.26M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 230.31M | 12.36% |
| Gross profit | 156.15M | 11.75% |
| Net profit | 47.26M | 12.35% |
| EBITDA | 72.59M | 6.25% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.7B |
Number of shares | 201.62M |
52-week high/low | €37.01 - €27.77 |
Dividend yield | 0.64% |
Dividends TTM | €0.21 |
Beta | 0.71 |
P/E ratio | 38.74 |
PEG ratio | 1.42 |
P/B ratio | 7.48 |
P/S ratio | 7.70 |
Company profile
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
| Name | ALK-Abelló B Aktie |
| CEO | Peter Halling |
| Headquarters | Horsholm,
cr Denmark |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 03/10/2000 |
| Employees | 2,721 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Nasdaq Copenhagen | ALK-B.CO |
Pnk | AKBLF |
Copenhagen | ALK B.CO |
Frankfurt | 4AJ0.F |
Düsseldorf | 4AJ0.DU |
London | 0OIR.L |
München | 4AJ0.MU |